As filed with the United States Securities and Exchange Commission on November 12, 2003
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
Under
THE SECURITIES ACT OF 1933
BIOGEN IDEC INC.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction
of incorporation or organization)
33-0112644
(I.R.S. Employer
Identification No.)
14 Cambridge Center
Cambridge, Massachusetts 02142
(Address of Principal Executive Offices)
2003 Omnibus Equity Plan
(Full title of the plan)
Thomas J. Bucknum, Esq.
Biogen Idec Inc.
Executive Vice President, General Counsel and Secretary
14 Cambridge Center
Cambridge, Massachusetts 02142
(617) 679-2000
(Name, address and telephone number, including area code, of agent for service)
CALCULATION OF REGISTRATION FEE
Title of Securities To Be Registered |
Amount to Be Registered(1) |
Proposed Maximum Offering Price per Share(2) |
Proposed Maximum Aggregate Offering Price(2) |
Amount of Registration Fee(2) |
||||
---|---|---|---|---|---|---|---|---|
Common Stock, $0.0005 par value per share | 17,400,000 shares | $32.965 | $573,591,000 | $6,836 |
PART I
INFORMATION REQUIRED IN THE SECTION 10(A) PROSPECTUS
Item 2: Registrant Information and Employee Plan Annual Information*
I-1
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 3: Incorporation of Documents by Reference
The following documents, which have been previously filed by the Registrant with the United States Securities and Exchange Commission (the "Commission"), are hereby incorporated by reference into this Registration Statement:
Until such time that a post-effective amendment to this Registration Statement has been filed which indicates that all securities offered hereby have been sold or which deregisters all securities remaining unsold at the time of such amendment, all documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934 shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of filing of such documents. Any statement contained herein or in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document which is also deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.
Item 4: Description of Securities
Not applicable.
Item 5: Interests of Named Experts and Counsel
Not applicable.
Item 6: Indemnification of Directors and Officers
The Registrant's Amended and Restated Certificate of Incorporation limits the liability of directors to the maximum extent permitted by Delaware law. Delaware law provides that directors of a corporation will not be personally liable for monetary damages for breach of their fiduciary duties as directors, except for liability for (i) any breach of their duty of loyalty to the corporation or its
II-1
stockholders, (ii) any acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii) any unlawful payments of dividends or unlawful stock purchases or redemptions as provided in Section 174 of the Delaware General Corporation Law or (iv) any transaction from which the director derived an improper personal benefit.
The Registrant's Bylaws provide that the Registrant shall indemnify its directors and may indemnify its officers and employees and other agents to the fullest extent permitted by law. The Registrant believes that indemnification under its Bylaws covers at least negligence and gross negligence on the part of indemnified parties.
The Registrant's Bylaws also permit the Registrant to secure insurance on behalf of any officer, director, employee or other agent for any liability arising out of his or her actions in such capacity, regardless of whether the Bylaws have the power to indemnify him or her against such liability under the General Corporation Law of Delaware. The Registrant currently has secured such insurance on behalf of its directors and officers.
The Registrant has entered into agreements to indemnify its directors and executive officers, in addition to indemnification provided for in its Bylaws. These agreements, among other things, indemnify the Registrant's directors and executive officers for certain expenses (including attorneys' fees), judgments, fines and settlement amounts incurred by any such person in any action or proceeding, including any action by or in the right of the Registrant, arising out of such person's services as a director or executive officer of the Registrant, any subsidiary of the Registrant or any other company or enterprise to which the person provides services at the Registrant's request. The Registrant believes that these provisions and agreements are necessary to attract and retain qualified persons as directors and executive officers.
Item 7: Exemption from Registration Claimed
Not applicable.
Exhibit Number |
Description |
|
---|---|---|
4.1(1) | Description of Common Stock. | |
5.1 |
Opinion of Pillsbury Winthrop LLP. |
|
23.1 |
Consent of Independent AuditorsKPMG LLP. |
|
23.2 |
Consent of Pillsbury Winthrop LLP (included in Exhibit 5.1). |
|
23.3 |
Consent of Independent AccountantsPricewaterhouseCoopers LLP. |
|
24.1 |
Powers of Attorney (included in signature page to Registration Statement). |
|
99.1(2) |
2003 Omnibus Equity Plan. |
II-2
(a) The undersigned Registrant hereby undertakes:
(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:
(i) To include any prospectus required by Section 10(a)(3) of the Securities Act; and
(ii) To reflect in the prospectus any facts or events arising after the effective date of this Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement; and
(iii) To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement; and
(2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof; and
(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.
(b) The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant's annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan's annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in this Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
(c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.
II-3
Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Cambridge, Commonwealth of Massachusetts on this 12th day of November 2003.
BIOGEN IDEC INC. | ||||
By: |
/s/ JAMES C. MULLEN James C. Mullen Chief Executive Officer and President |
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Thomas J. Bucknum and Anne Marie Cook and each of them, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-facts and agents, or either of them, or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.
Signature |
Title |
Date |
||
---|---|---|---|---|
/s/ JAMES C. MULLEN James C. Mullen |
Chief Executive Officer, President and Director (Principal Executive Officer) |
November 12, 2003 |
||
/s/ PETER N. KELLOGG Peter N. Kellogg |
Executive Vice President, Finance and Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) |
November 12, 2003 |
||
/s/ WILLIAM H. RASTETTER William H. Rastetter, Ph.D. |
Executive Chairman and Director |
November 12, 2003 |
||
Alan Belzer |
Director |
November , 2003 |
||
Lawrence C. Best |
Director |
November , 2003 |
||
/s/ ALAN B. GLASSBERG Alan B. Glassberg, M.D. |
Director |
November 12, 2003 |
||
Mary L. Good, Ph.D. |
Director |
November , 2003 |
||
II-4
Thomas F. Keller, Ph.D. |
Director |
November , 2003 |
||
/s/ ROBERT W. PANGIA Robert W. Pangia |
Director |
November 12, 2003 |
||
/s/ BRUCE R. ROSS Bruce R. Ross |
Director |
November 12, 2003 |
||
/s/ LYNN SCHENK Lynn Schenk |
Director |
November 12, 2003 |
||
Phillip A. Sharp, Ph.D. |
Director |
November , 2003 |
||
/s/ WILLIAM D. YOUNG William D. Young |
Director |
November 12, 2003 |
II-5
Exhibit Number |
Description |
|
---|---|---|
4.1(1) | Description of Common Stock. | |
5.1 |
Opinion of Pillsbury Winthrop LLP. |
|
23.1 |
Consent of Independent Auditors KPMG LLP. |
|
23.2 |
Consent of Pillsbury Winthrop LLP (included in Exhibit 5.1). |
|
23.3 |
Consent of Independent AccountantsPricewaterhouseCoopers LLP. |
|
24.2 |
Powers of Attorney (included in signature page to Registration Statement). |
|
99.1(2) |
2003 Omnibus Equity Plan. |
II-6
Pillsbury
Winthrop LLP
101 West Broadway, Suite 1800
San Diego, California 92101
November 12, 2003
Biogen
Idec Inc.
14 Cambridge Center
Cambridge, Massachusetts 02142
Re: Registration Statement on Form S-8
Ladies and Gentlemen:
We are acting as counsel for Biogen Idec Inc., a Delaware corporation (the "Company"), in connection with the Registration Statement on Form S-8 (the "Registration Statement") relating to the registration under the Securities Act of 1933 (the "Act") of Seventeen Million Four Hundred Thousand (17,400,000) shares of the Company's Common Stock, par value $0.0005 per share (the "Shares"), issuable pursuant to certain stock option agreements and stock purchase agreements by the Company (collectively, the "Agreements").
We have reviewed and are familiar with such corporate proceedings and other matters as we have deemed necessary for this opinion. Based upon the foregoing, we are of the opinion that the Shares have been duly authorized and, when issued and sold in accordance with the Agreements, will be legally issued, fully paid and nonassessable. This opinion is limited to matters governed by the General Corporation Law of the State of Delaware.
We hereby consent to the filing of this opinion as Exhibit 5.1 to the Registration Statement. In giving this consent, we do not thereby admit that we are within the category of persons whose consent is required under Section 7 of the Act or the rules and regulations of the Securities and Exchange Commission promulgated thereunder.
Very truly yours, | |
/s/ PILLSBURY WINTHROP LLP |
CONSENT OF INDEPENDENT AUDITORS
The
Board of Directors
Biogen Idec Inc:
We consent to the use of our report dated January 29, 2003, appearing in the Annual Report on Form 10-K of IDEC Pharmaceuticals Corporation as of December 31, 2002 and 2001, and for each of the years in the three-year period ended December 31, 2002, incorporated herein by reference in the Form S-8 Registration Statement expected to be filed on or about November 12, 2003.
/s/ KPMG LLP
San
Diego, California
November 12, 2003
CONSENT OF INDEPENDENT ACCOUNTANTS
We hereby consent to the incorporation by reference in the Biogen Idec Inc. Registration Statement on Form S-8 of our report dated February 14, 2003 relating to the financial statements of Biogen, Inc., which is included in the Biogen Idec Inc. Current Report on Form 8-K dated November 12, 2003.
/s/ PricewaterhouseCoopers LLP
Boston,
Massachusetts
November 12, 2003